

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Levy, Ronald, MD		POSITION TITLE Professor of Medicine; Chief, Division of Oncology	
eRA COMMONS USER NAME (credential, e.g., agency login) LEVY.RONALD			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
Harvard University, Boston, Massachusetts	AB	06/63	Biochemistry
Stanford University, Stanford, California	MD	06/68	Medicine

Personal Statement

I have had a long history of research and accomplishments in the field of immunotherapy, beginning with the original development of monoclonal antibodies for the treatment of lymphoma and extending to active vaccine development. I have also trained scores of MD and PhD postdoctoral fellows and students. Our lab and translational research effort is very active with 8 current postdoctoral fellows and students and active lab meetings and journal clubs.

Positions

1968-1969 Internship Internal Medicine, Massachusetts General Hospital, Boston, MA
 1969-1970 Residency Internal Medicine, Massachusetts General Hospital, Boston, MA
 1970-1972 Clin. Assoc., Immunology Branch, National Cancer Institute, Bethesda, MD
 1972-1973 Fellow, Department of Medicine, Division of Oncology, Stanford University
 1973-1975 Fellow of the Helen Hay Whitney Foundation, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel
 1975-1981 Assistant Professor of Medicine, Division of Oncology, Stanford University
 1981-1987 Associate Professor of Medicine, Division of Oncology, Stanford
 1987-Present Professor of Medicine, Division of Oncology, Stanford University School of Medicine
 1987-Present Robert K. Summy and Helen K. Summy Professor, Stanford University
 1993-Present Chief of the Division of Oncology, Stanford University School of Medicine

Honors

1977 Investigator, Howard Hughes Medical Institute
 1979 Member, American Society of Clinical Investigation
 1982 Armand Hammer Award for Cancer Research
 1983 Ciba-Geigy Drew Award in Biomedical Research
 1987 Member, Association of American Physicians
 1987 American Cancer Society Clinical Research Professorship
 1989 Joseph Steiner Prize
 1997 Joseph H. Burchenal, Clin. Cancer Res. Award, American Assoc. for Cancer Research
 1999 Karnofsky Award, American Society of Clinical Oncology
 1999 Charles Kettering Prize, General Motors Cancer Research Foundation
 2000 C.Chester Stock Award, Memorial Sloan-Kettering Cancer Center
 2000 Medal of Honor, American Cancer Society
 2000 Key to the Cure Award, Cure For Lymphoma Foundation
 2001 Evelyn Hoffman Memorial Award, Lymphoma Research Foundation of America
 2003 Jeffrey A. Gottlieb Memorial Award, M.D. Anderson Cancer Center
 2004 Damashek Prize, American Society of Hematology
 2007 Member, Institute of Medicine of the National Academies
 2007 di Villers International Achievement Award, Leukemia and Lymphoma Society

2008 Member, National Academy of Sciences
 2009 King Faisal International Prize, The King Faisal Foundation

Publications (recent publications out of 265)

- Timmerman J, Vose J, Czerwinski D., Weng Wen-Kai, Ingolia D, Mayo, M, Denny D, Levy R., Tumor-Specific Recombinant Idiotypic Immunization After Chemotherapy as Initial Treatment for Follicular Non-Hodgkin's Lymphoma. *Leuk Lymphoma*. 2009 Jan; 50(1):1-2 PMC Journal - In Process
- Houot R, Levy R. Idiotypic vaccination for lymphoma: moving towards optimisation. *Leuk Lymphoma*. 2009 Jan;50(1):1-2 PMC Journal - In Process
- Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. *Am J Clin Pathol*. 2009 Feb;131(2):264-78 PMC Journal - In Process
- Weiyun Z. Ai, Robert Tibshirani, Behnaz Taidi, Debra Czerwinski, and Ronald Levy, Anti-idiotypic antibody response after vaccination correlates with better overall survival in follicular lymphoma *Blood*, Apr 2009; doi:10.1182/blood-2009-01-201988 PMCID: PMC2700314
- Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab *Leuk Lymphoma*. 2009 May;50(5):723-7. PMC Journal – in Process
- Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond, *Blood Rev*. 2009 May;23(3):137-42 PMC Journal – in Process
- Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-B-cell lymphoma. *N Engl J Med*. 2009 Jun 25;360(26):2794-5. PMC Journal – in Process
- Varghese B, Widman A, Do J, Taidi B, Czerwinski DK, Timmerman J, Levy S, Levy R. Generation of CD8+T cell-mediated immunity against idiotype negative lymphoma escapees. *Blood*. 2009 Sep 17. PMCID: PMC2777127
- Patel KG, Ng PP, Kuo CC, Levy S, Levy R, Swartz JR., Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. *Biochem Biophys Res Commun*. 2009 Dec 18;390(3):971-6. PMC Journal – in Process
- Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, Levy R, Levy S, Natkunam Y. CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. *Hum Pathol*. 2010 Feb;41(2):271-80. PMCID: PMC2813949
- Anderson MW, Zhao S, Ai WZ, Tibshirani R, Levy R, Lossos IS, Natkunam Y., C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.. *Am J Clin Pathol*. 2010 Mar;133(3):473-83. PMC Journal – in Process
- Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R., Inaugural Article: B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. *Proc Natl Acad Sci U S A*. 2010 Jun 11. PMC Journal – in Process
- Joshua D. Brody, Weiyun Z. Ai, Debra K. Czerwinski, James A. Torchia, Mia Levy, Ranjana H. Advani, Youn H. Kim, Richard T. Hoppe, Susan J. Knox, Lewis K. Shin, Irene Wapnir, Robert J. Tibshirani, Ronald Levy, In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study, *J. Clin Onc*. June 16 2010 PMID: 20697067
- Younes SF, Beck AH, Lossos IS, Levy R, Warnke RA, Natkunam Y. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. *Am J Surg Pathol*. 2010 Sep;34(9):1266-76. PMCID: PMC2929284
- Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. *Cell*. 2010 Sep 3;142(5):699-713. PMID: 20813259
- Patel KG, Ng PP, Levy S, Levy R, Swartz JR, Escherichia coli-based production of a tumor idiotype antibody fragment - tetanus toxin fragment C fusion protein vaccine for B cell lymphoma., *Protein Expr Purif*. 2011 Jan;75(1):15-20. Epub 2010 Sep 19. PMID: 20851769
- Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R, A CpG-loaded tumor cell vaccine induces anti-tumor CD4+ T cells that are effective in adoptive therapy for large and established tumors, *Blood*. 2010 Sep 27. [Epub ahead of print] PMID: 20876455

in Lymphoma.